...be delivered via a non-invasive intranasal device to the CNS, bypassing the blood-brain barrier. Impel Neuropharm...

...Therapeutics Inc. has arbaclofen (STX209) in Phase II testing for ASDs and Fragile X syndrome. Neuropharm Group plc...

...STX107 from Seaside Therapeutics Inc. is in Phase I for fragile X, and NPL-2009 from Neuropharm Group plc...
...Switzerland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Michael J. Fox Foundation , New York, N.Y. Neuropharm Group plc...

...inhibitor (SSRI), which uses Zydis drug delivery technology from Catalent Pharma Solutions Inc. (Somerset, N.J.). Neuropharm Group plc...

...Neuropharm retained Piper Jaffray Ltd. to advise on a sale or merger of the biotech. Neuropharm...
...was in negotiations that may or may not lead to a sale of the company. Neuropharm...
...an update on the negotiations no later than at its annual general meeting Dec. 9. Neuropharm's...

...was not disclosed. The compound was well tolerated with no serious adverse events. Last year, Neuropharm...
...complete the submission next quarter. The company did not disclose its plans for the compound. Neuropharm...
...Orphan designations in the U.S. to treat autism. Catalent Pharma Solutions Inc. , Somerset, N.J. Neuropharm Group plc...

...to start Phase III testing mid-year. The ceramide analog inhibits glucosylceramide synthase (see B12) . Neuropharm...
...the Phase III SOFIA trial to treat autism showed that NPL-2008 missed the primary endpoint. Neuropharm...

...Submit NDA 2H09 Neurobiological (NASDAQ:NTII) Viprinex ancrod Acute ischemic stroke Final Ph III data Mid-2009 Neuropharm...

...developed using the Zydis delivery technology from Catalent. Catalent Pharma Solutions Inc. , Somerset, N.J. Neuropharm Group plc...